AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01670812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFP+HDMP+Rituximab
Description: This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
Study NCT03966495 — intervention group
Intervention type: OTHER
Intervention: Sustainability of a research program in risk management
Description: No intervention will be implemented in the present study.~The investigators will evaluate of the sustainability of a research program in risk management in pluriprofessional primary care offices:~* Qualitatively assessed safety culture and Sustainability of the PRisM RM program in the offices by interviews of professional belonging to the offices.~* Quantitatively assessed safety climate in the offices measured by the Medical Office Survey on Patient Safety Culture (MOSPS) Questionnaire (fill in by the professionals of the offices)
Study NCT03472820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Recommendations
Description: Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.
Study NCT03472820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Management Recommendations
Description: Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.
Study NCT03472820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PhytoGanix (tropical fruit flavor)
Description: Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.
Study NCT03472820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UltraFlora Intensive Care
Description: Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
Study NCT04124055 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM)
Description: Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted
Study NCT03465384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comet
Description: The intervention is a behaviorally based and manualized parent training program.
Study NCT03465384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comet
Description: The intervention is a behaviorally based and manualized parent training program.
Study NCT00829127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8075
Description: single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
Study NCT00829127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study NCT00565812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SD-6010
Description: 200 mg tablets once a day for 2 years
Study NCT01766037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspiration Therapy (AspireAssist)
Description: Use of the AspireAssist device in aspiration therapy
Study NCT01766037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Therapy
Description: Lifestyle therapy is a behavioral, diet and physical activity education program
Study NCT01766037 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Therapy
Description: Lifestyle therapy is a behavioral, diet and physical activity education program
Study NCT04544644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104+anlotinib
Description: AK 104 is given by intravenous infusion and anlotinib is given by oral.
Study NCT01268046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol oral capsule
Description: 1 oral capsule (1 mg estradiol) administered daily for one month
Study NCT01268046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transderman estrogen patch
Description: transdermal estrogen patch (50 mcg/day) for one month
Study NCT01268046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: trasdermal placebo patch
Description: transdermal placebo patch with patch change every 84 hr for one month
Study NCT00565812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SD-6010
Description: 50 mg tablets once a day for 2 years
Study NCT00565812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once a day for 2 years
Study NCT01268046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo oral capsule
Description: placebo oral capsule administered daily for one month.
Study NCT01771991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Sodermix Dismutase in the form of Sodermix (SOD)
Description: Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
Study NCT04423757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: 125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
Study NCT04423757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
Study NCT01771991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
Study NCT02859285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vulvar cream
Study NCT02859285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol vulvar cream
Study NCT02967549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: NAVA delivered by the Servo-n ventilator (Maquet)
Study NCT02129595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
Study NCT04436900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation (PRP)
Description: PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
Study NCT03010267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R213
Description: Investigational product is prescribed to all of randomized subjects
Study NCT03010267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Investigational product is prescribed to all of randomized subjects
Study NCT03010267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecaliferol
Description: Investigational product is prescribed to all of randomized subjects
Study NCT00361218 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: open-label selective serotonin reuptake inhibitor (SSRI)
Description: Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
Study NCT03707262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor CD34+ and CD3+ cells
Description: Infusion of GCSF-mobilized, Miltenyi-enriched CD34+ hematopoietic stem/progenitor cells (HSPCs) (≥ 5 million cells/kg) and CD3+ cells (5 million cells/kg) from an HLA-identical sibling living donor, following pre-conditioning regimen of rATG and TLI.
Study NCT00546507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDS-943 (topical diclofenac sodium 4% spray)
Study NCT00546507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Study NCT00546507 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02691364 — intervention group
Intervention type: PROCEDURE
Intervention: Blood withdrawal
Study NCT00718523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
Study NCT00718523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 479 Placebo
Description: Matching placebo administered Day 1 of each 21 day cycle.
Study NCT01425853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin/Glucosamine (Droglican)
Description: Experimental
Study NCT01425853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Active comparator
Study NCT04110184 — intervention group
Intervention type: OTHER
Intervention: Systemic lupus erythematosus disease activity index (SLEDAI)
Description: The SLEDAI score ranges between 0 and 105, and scores ≥8 represent active disease
Study NCT01278420 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tecnis MF
Description: 30 subjects will be implanted with the Tecnis MF
Study NCT01278420 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ReSTOR
Description: 30 subjects will be implanted with ReSTOR
Study NCT00995696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PhaST IVR Calls
Description: Participants in this condition receive 7 computer automated IVR calls.
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: All patients will be randomly assigned to receive thalidomide 400 mg as an oral, once daily dose throughout induction and 100mg between transplants after platelets are greater than 50,000μl and 200 mg post transplant consolidation, and a reduced dose of 100 mg on alternating days during the first year of maintenance and 50 mg qod thereafter versus no thalidomide. Thalidomide will be held during conditioning, transplant procedure, and recovery following transplant. It may be resumed once plateletrecovery is complete after each transplant
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: Cytarabine (Ara-C) 400 mg/m2 in 250 ml D5W over one hour daily for four days (on days -5, -4, -3, -2).~Start infusion 30 minutes after completion of BCNU on day -5.
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCNU
Description: Carmustine (BCNU) 300 mg/m2 in 1 liter of D5W in glass bottle (protect from light) to infuse over 2 hours on day -5. Check blood pressure every 15 minutes during infusion and 30 minutes after completion
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin\* 15 mg/m2/day Continuous infusion 1-4 (DCEP CYCLE 2) Cisplatin\* 7.5 mg/m2 Continuous infusion 1-4 (DPACE cycle)~\*Cisplatin doses will be modified for renal insufficiency as follows: Cisplatin dose Creatinine 15 mg/m2 (full dose) \< 1.5 mg/dl 10 mg/m2 1.6 - 2.0 mg/dl 7.5 mg/m2 2.1 - 3.0 mg/dl 0 mg (hold Cisplatin) > 3.0 mg/dl
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytoxan
Description: Cycle 2 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cycle 3 - CAD and PBSC Collection #1 Cyclophosphamide 750 mg/m2/day Continuous infusion 1-4 Cycle 4 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cytoxan/VP-16 and PBSC Collection-Cyclophosphamide 2 grams/m2 (Total dose 4 gm/m2) IV by CI 1 and 2 Post-Transplant Consolidation-Cyclophosphamide 300 mg/m2 Continuous infusion 1-4
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as \< 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20
Study NCT00577915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiology/MRI scan
Description: MRI spectroscopy
Study NCT00217009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband Ultraviolet B (TL-01UVB) Therapy
Study NCT00217009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Topical Psoralen plus ultraviolet A (PUVA)
Study NCT03255304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health mindest
Description: groups be confronted with health aspects of food items
Study NCT02967549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAV
Description: PAV delivered by the Stephanie ventilator (Stephan)
Study NCT03697161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101 (gaboxadol)
Description: OV101 (gaboxadol)
Study NCT00126191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
Study NCT00126191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)
Study NCT00126191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
Study NCT00126191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
Study NCT04263116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Assisted Maturation
Description: Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein
Study NCT03255304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: palatability mindset
Description: groups be confronted with palatability aspects of food items
Study NCT01907776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1100 inhalation solution
Description: ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
Study NCT00126191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle
Study NCT00126191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
Study NCT01907776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ME1100 placebo inhalation solution
Description: Vehicle placebo
Study NCT00841269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uridine
Description: Uridine 500 mg by mouth twice per day for 6 weeks
Study NCT03846167 — intervention group
Intervention type: DRUG
Intervention: Imaging Drug FluorThanatrace (FTT)
Description: \[18F\]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
Study NCT02715492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH
Description: (Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
Study NCT02715492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Trans arterial chemoembolization
Study NCT02715492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Trans arterial chemoembolization
Study NCT01092026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cord blood transplantation
Description: One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
Study NCT03127579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Longer meal duration
Description: Participants have 50% more time to eat than usual
Study NCT02206321 — intervention group
Intervention type: PROCEDURE
Intervention: Navigation total knee arthroplasty
Description: computer assisted navigation total knee arthroplasty without femur intramedullary involvement
Study NCT02206321 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional total knee arthroplasty
Description: conventional technique with femur intramedullary violation
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
Study NCT00126191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
Study NCT01192841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician uniform
Description: Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
Study NCT01920438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy
Description: PEG
Study NCT01920438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologically-guided insertion of Gastrostomy
Description: RIG
Study NCT00640146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant GM-CSF
Description: GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alpha-2b
Description: AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
Study NCT00083551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.
Study NCT02104791 — intervention group
Intervention type: DRUG
Intervention: procalcitonin
Description: In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
Study NCT01488461 — intervention group
Intervention type: GENETIC
Intervention: blood sample
Description: Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
Study NCT01844297 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TDF+3TC+EFV
Study NCT03666520 — intervention group
Intervention type: OTHER
Intervention: Clinical Decision Support prompted to the clinician to convert drug.
Description: This study is designed to further research the conversion of Intravenous medications to oral medications in patients in an inpatient setting whenever it is appropriate and safe. We have chosen eight medications to research in this study. These medications were chosen because large difference in cost between an intravenous (IV) dose of this medication versus an oral (PO) dose of this medication exist. This study aims to further evaluate the appropriateness and safety of converting IV medications to PO medications for hospitalized patients through a pilot clinical trial.